Search alternatives:
point decrease » point increase (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 de » 2 d (Expand Search), _ de (Expand Search), i de (Expand Search)
point decrease » point increase (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 de » 2 d (Expand Search), _ de (Expand Search), i de (Expand Search)
-
39781
A398 induces apoptosis in HL-60 cell line.
Published 2014“…<p>Cells were treated with A398 (4, 6 and 8 µM) or etoposide (5 µM) for 1 h, 3 h or 6 h and stained with annexin V-alexa fluor 488 and PI or with TMRM. …”
-
39782
-
39783
Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension
Published 2017“…Decreases of both systolic (P = 0.06) and diastolic (P = 0.04) blood pressure after amlodipine administration tended to associate with a decrease of plasma hexadecanedioate, a dicarboxylic fatty acid recently linked to blood pressure regulation.…”
-
39784
Table2_Identification of an Autophagy-Related Gene Signature for the Prediction of Prognosis in Early-Stage Colorectal Cancer.XLSX
Published 2021“…The ATG signature, stratifying patients into high and low autophagy risk groups, was validated in the validation (HR, 2.29[1.15–4.55]; p = 1.5 × 10–2) and meta-validation cohorts (HR, 2.5[1.03–6.06]; p = 3.63 × 10–2) and proved to be prognostic in a multivariate analysis. …”
-
39785
Image2_Identification of an Autophagy-Related Gene Signature for the Prediction of Prognosis in Early-Stage Colorectal Cancer.TIF
Published 2021“…The ATG signature, stratifying patients into high and low autophagy risk groups, was validated in the validation (HR, 2.29[1.15–4.55]; p = 1.5 × 10–2) and meta-validation cohorts (HR, 2.5[1.03–6.06]; p = 3.63 × 10–2) and proved to be prognostic in a multivariate analysis. …”
-
39786
Data_Sheet_1_A Secondary Metabolism Pathway Involved in the Production of a Putative Toxin Is Expressed at Early Stage of Monilinia laxa Infection.xlsx
Published 2022“…We identified a class of genes highly expressed at 6 hpi and that their expression decreased to almost undetectable levels at 14 to 48 hpi. …”
-
39787
Table_1_A novel form of transcutaneous electrical nerve stimulation for the reduction of dysesthesias caused by spinal nerve dysfunction: A case series.docx
Published 2022“…Background<p>Current therapeutic interventions for dysesthesias caused by spinal cord dysfunctions are ineffective. We propose a novel intervention using transcutaneous electrical nerve stimulation (TENS) for dysesthesias, and we present an in-depth case series.…”
-
39788
A Pilot Trial of a Sexual Health Counseling Intervention for HIV-Positive Gay and Bisexual Men Who Report Anal Sex without Condoms
Published 2016“…</p><p>Trial Registration</p><p>ClinicalTrials.gov <a href="http://www.clinicaltrials.gov/ct2/show/NCT02546271" target="_blank">NCT02546271</a></p></div>…”
-
39789
Table_2_A novel form of transcutaneous electrical nerve stimulation for the reduction of dysesthesias caused by spinal nerve dysfunction: A case series.docx
Published 2022“…Background<p>Current therapeutic interventions for dysesthesias caused by spinal cord dysfunctions are ineffective. We propose a novel intervention using transcutaneous electrical nerve stimulation (TENS) for dysesthesias, and we present an in-depth case series.…”
-
39790
Table_3_A novel form of transcutaneous electrical nerve stimulation for the reduction of dysesthesias caused by spinal nerve dysfunction: A case series.docx
Published 2022“…Background<p>Current therapeutic interventions for dysesthesias caused by spinal cord dysfunctions are ineffective. We propose a novel intervention using transcutaneous electrical nerve stimulation (TENS) for dysesthesias, and we present an in-depth case series.…”
-
39791
Image_1_Lipocalin 2 – mutation screen and serum levels in patients with anorexia nervosa or obesity and in lean individuals.pdf
Published 2023“…The secondary structure change of lipocalin-2 due to LCN2-p.Val89Ile may decrease solubility and results in a low lipocalin-2 level in a heterozygotes carrier (female recovered from AN). …”
-
39792
Flow chart of study selection.
Published 2024“…ID=CRD42022339649" target="_blank">CRD42022339649</a>.</p></div>…”
-
39793
DataSheet_1_Association between GLO1 variants and gestational diabetes mellitus susceptibility in a Chinese population: a preliminary study.zip
Published 2023“…Conversely, the GLO1 rs4746 TG was associated with a decreased risk of GDM (TG vs. TT: OR = 0.740; 95% CI: 0.548-0.999; P = 0.049; TG vs. …”
-
39794
A Functional Polymorphism (rs10817938) in the XPA Promoter Region Is Associated with Poor Prognosis of Oral Squamous Cell Carcinoma in a Chinese Han Population
Published 2016“…In conclusion, the present study showed that XPA rs10817938 polymorphism is a functional SNP in <i>vitro</i> and in <i>vivo</i> and a biomarker for poor prognosis in OSCC patients.…”
-
39795
-
39796
-
39797
-
39798
Flow chart of data screening and analysis.
Published 2025“…In contrast, the BMD, BV/TV, and Tb.N in the 12-week model group exhibited a modest but non-significant decrease relative to the 9-week model group. …”
-
39799
A watermaze protocol to examine competition of two memory traces.
Published 2017“…<p>(A) Rats learned two opposite hidden platform locations in a watermaze over two successive sessions (four blocks of two trials per block, separated by 7.5 h) with a probe trial (no platform) conducted 7 d later. …”
-
39800
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
Published 2017“…Total cholesterol (-0.3±0.6 mmol/L) and non-HDL cholesterol (-0.3±0.5 mmol/L) significantly decreased from baseline to Week 12 in the tesamorelin 2 mg group (p<0.05 vs. placebo). …”